Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T21:03:27.994Z.
Calculation as of: 2026-10-06T21:03:27.994Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c51f7bb38e0467dbdaec2b87e904118633479c78190bb705d814f7e841715b6d
PE RATIO
N/A
Market Cap
$2.17B
PE Ratio
N/A
TTM Avg
6.84
3Y Avg
18.15
5Y Avg
20.42
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | $2.11B | N/A | N/A | N/A | N/A |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | N/A | N/A | N/A | N/A |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 19.85 | 21.19 | 24.83 | 28.15 |
| GeneDx Holdings Corp. (WGS)vs › | $2.13B | N/A | 3863.54 | 3863.54 | 3863.54 |
| Alvotech (ALVO)vs › | $2.08B | N/A | 33.55 | 33.55 | 33.55 |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | N/A | N/A | N/A | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | N/A | N/A | N/A | N/A |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.17B | N/A | 6.84 | 18.15 | 20.42 |
| Vericel Corporation (VCEL)vs › | $2.05B | 85.61 | 135.31 | 1187.07 | 1145.73 |
| Pharvaris N.V. (PHVS)vs › | $2.17B | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$11.34
Forward EPS (Est.)
$-0.20
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
